News about Global Pharma

Zydus Acquires 85.6 Percent Stake in Amplitude Surgical for EUR 256 Million

Zydus Acquires 85.6 Percent Stake in Amplitude Surgical for EUR 256 Million

Zydus Lifesciences Ltd. has completed the EUR 256 million acquisition of an 85.6 percent stake in France-based Amplitude Surgical, marking a strategic move to strengthen its global presence in the orthopaedics space.

Global Pharma | 30/07/2025 | By Mrinmoy Dey |  238

Novo Nordisk Appoints Maziar Mike Doustdar as New CEO, Announces Key Organisational Changes

Novo Nordisk Appoints Maziar Mike Doustdar as New CEO, Announces Key Organisational Changes

Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen, who will step down as President and Chief Executive Officer of Novo Nordisk next month.

Global Pharma | 30/07/2025 | By Dineshwori |  892

Johnson and Johnson Unveils AI Solution for Bunion Surgery, Seeks FDA Nod to Expand TREMFYA Label

Johnson and Johnson Unveils AI Solution for Bunion Surgery, Seeks FDA Nod to Expand TREMFYA Label

Johnson and Johnson MedTech has announced the launch of the VIRTUGUIDE System, an advanced AI-powered solution designed to support Lapidus procedures—a common type of bunion surgery.

Global Pharma | 30/07/2025 | By Dineshwori |  210

Novo Nordisk Cuts Annual Outlook Again as Wegovy Supply Woes Persist

Novo Nordisk Cuts Annual Outlook Again as Wegovy Supply Woes Persist

Shares of Novo Nordisk fell sharply after the company once again lowered its annual forecast, citing ongoing supply challenges for its blockbuster obesity drug Wegovy. Despite a 25% jump in second-quarter sales and a 28% rise in net profit, the Danish drugmaker scaled back expectations for full-year operating profit and sales growth.

Global Pharma | 30/07/2025 | By Darshana |  157

Novartis India Appoints DC Dave and Co as Cost Auditors for FY 2025-26

Novartis India Appoints DC Dave and Co as Cost Auditors for FY 2025-26

Novartis India has appointed M/s. DC Dave and Co., a firm of practicing cost accountants, as the cost auditors of the company for the financial year 2025–26.

Global Pharma | 29/07/2025 | By Dineshwori |  272

Veranova Names Thomas Rohrer as Vice President of Bioconjugation

Veranova Names Thomas Rohrer as Vice President of Bioconjugation

Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, has appointed Thomas Rohrer as Vice President of Bioconjugation.

Global Pharma | 29/07/2025 | By Dineshwori |  370

Dr. Reddy's Injects INR 565 Crore into Russian Arm

Dr. Reddy's Injects INR 565 Crore into Russian Arm

Dr Reddy’s Laboratories Ltd has invested INR 565.4 crore in its Russian arm, Dr Reddy’s Laboratories LLC (DRL Russia), acquiring a 45.19 percent equity stake in the step-down wholly-owned subsidiary.

Global Pharma | 29/07/2025 | By Dineshwori |  950

PTC Therapeutics Secures US FDA Approval for SEPHIENCE

PTC Therapeutics Secures US FDA Approval for SEPHIENCE

PTC Therapeutics has received FDA approval for SEPHIENCE (sepiapterin) to treat sepiapterin-responsive phenylketonuria (PKU) in patients aged one month and older, offering a new therapy for managing this rare metabolic disorder.

Global Pharma | 29/07/2025 | By Mrinmoy Dey |  401

Kinvard Bio Secures USD 2.7 Million Funding from CARB-X to Accelerate Development of Next-Generation Antibiotics

Kinvard Bio Secures USD 2.7 Million Funding from CARB-X to Accelerate Development of Next-Generation Antibiotics

Kinvard Bio has secured USD 2.7 million in follow-on non-dilutive funding from CARB-X to advance its novel ribosome-targeting antibiotics toward preclinical development, tackling drug-resistant infections like MRSA and cUTI.

Global Pharma | 29/07/2025 | By Mrinmoy Dey |  300

AstraZeneca Reports 11 Percent Revenue Growth, Commits to USD 50 Bn US Expansion

AstraZeneca Reports 11 Percent Revenue Growth, Commits to USD 50 Bn US Expansion

For H1 2025, AstraZeneca’s total revenue rose 11 percent at constant exchange rates (CER) to USD 28.0 billion, driven by double-digit growth in both its oncology and biopharmaceuticals divisions.

Global Pharma | 29/07/2025 | By Dineshwori |  369

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members